Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Diagnosis of stage IV colorectal cancer (histologic proof is not required) * Measurable disease * Spiral CT scan required for both pre- and post-treatment tumor assessments of lesions measuring 1-2 cm * Progressive disease during or within 6 months of most recent prior chemotherapy regimen (bevacizumab, fluoropyrimidine, oxaliplatin, or irinotecan-based treatment) OR considered ineligible for standard therapy * Documentation of submission of tumor material for Kirsten Rat Sarcoma (KRAS) testing available * Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab or panitumumab) required for patients with wild-type KRAS tumor * No known brain metastasis * Patients with neurological symptoms must undergo a CT scan or MRI of the brain to exclude brain metastasis * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Life expectancy ≥ 6 months * Hemoglobin ≥ 9.0 g/dL * Absolute neutrophil count (ANC) ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * White blood cell count (WBC) ≥ 3,400/mm³ * International normalized ratio (INR) \< 1.5 (≤ 3.0 if on anti-coagulation therapy \[e.g., warfarin or heparin\]) * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * Aspartate aminotransferase (AST) ≤ 2.5 times ULN (≤ 5 times ULN if there is liver involvement) * Alkaline phosphatase ≤ 3 times ULN * Creatinine ≤ 1.5 times ULN * Urine protein:creatinine ratio \< 1 OR urine dipstick \< 2+ OR urine protein \< 1,000 mg by 24-…